Entero Healthcare Solutions Ltd

- As of now, Entero Healthcare Solutions Limited does not have any immediate plans for new fundraising through debt or equity. - The company has unutilized proceeds from its IPO and significant cash on its balance sheet, which it intends to use for future acquisitions. - Positive operating cash flows expected in the near future will further support acquisitions without the need for additional fundraising. - External capital will primarily be used for inorganic growth, leveraging IPO proceeds already raised. - Management has confirmed no immediate fundraising plans and prefers to utilize internal accruals and existing cash resources.

- No explicit mention of current or future capex or capital investment plans in the transcript. - Focus remains on inorganic growth through acquisitions; recently completed 10 acquisitions and pipeline continues. - Investments largely in acquisitions to expand geographic footprint, product portfolio, and capabilities. - Emphasis on operational efficiencies, technology-led solutions, and building a digitally integrated healthcare distribution platform. - Working capital improvements and margin expansion targeted to drive positive operating cash flows from FY ‘26. - No indication of large capex or strategic investments beyond acquisition-related spends. - Available IPO proceeds and positive operating cash flows expected to fund acquisitions without need for fresh fundraise as of now.

- Targeting over 30% revenue growth in FY ‘26, similar or better than FY ‘25’s 30% growth. - FY ‘25 growth comprised 16% organic growth and remaining from acquisitions; organic growth is expected to continue at 1.5x to 2x the Indian Pharmaceutical Market (IPM) growth rate. - IPM assumed growth is ~8%; therefore, organic growth is anticipated around 15%-16%. - Full-year impact of last year’s acquisitions expected to add approximately Rs. 500 crores. - New acquisitions in FY ‘26 expected to add over Rs. 400 crores in annualized revenues. - Long-term plan includes doubling down on organic expansion via new pharmacies, hospitals, and increased wallet share. - Growth strategy balanced between organic growth and margin-accretive inorganic acquisitions. - Anticipated shift towards organized distribution and digital integration to fuel expansion. - Expectations on sustained growth driven by geographically diversified operations and expanding product portfolio including specialty pharma, medical devices, and consumables.

- FY ‘26 revenue growth target: >30%, continuing the momentum from FY ‘25 (30% growth). - Organic growth expected at 1.5x to 2x of IPM growth rate; IPM industry growth estimated at 8-10%. - EBITDA margins targeted to exceed 4% on a full-year basis in FY ‘26, with medium-term aim of around 5% or slightly higher. - Positive operating cash flow anticipated in FY ‘26, driven by margin expansion and better working capital management (targeting 60-day working capital cycle). - Longer-term margin guidance withheld; management may share FY ‘27 guidance later. - Acquisitions are margin accretive and expected to add to profitability; inorganic growth planned but to normalize in 2 years. - Profit after tax grew 2.7x in FY ‘25, signaling robust operating leverage and financial execution improvements. Overall, Entero Healthcare aims double-digit organic growth, improving EBITDA margins to 4%+ in FY ‘26, and sustained profitability growth via acquisitions and operational efficiencies.

- The transcript does not explicitly mention a current or expected order book or pending orders. - Discussion focuses on acquisitions, integration timelines, and revenue growth guidance. - Prabhat Agarwal mentions a timeline of about two to two and a half months to close remaining acquisitions, aiming to complete sooner. - Total consideration for acquisitions is confidential; multiples are guided between 5x to 7x EV/EBITDA. - The company expects 30% revenue growth for FY '26 driven by organic growth and acquisitions. - No direct reference to order book or pending orders was made in the transcript on page 21 or surrounding pages.